Single Cell Transcriptomic and Epigenomic Dissection of Opioid and Cocaine Responses in HIV

HIV 中阿片类药物和可卡因反应的单细胞转录组和表观基因组解析

基本信息

批准号：
10478928
负责人：
Myriam Heiman
金额：
$ 244.79万
依托单位：
BROAD INSTITUTE, INC.
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10478928
关键词：
AIDS/HIV problem ATAC-seq Addictive Behavior Address Affect Amygdaloid structure Animal Model Animals Atlases Biological Biological Assay Biology Brain Brain region Cell physiology Cells Characteristics Chronic Cocaine Corpus striatum structure Country DNA Data Data Set Dementia Development Disease Disease Management Dissection Dorsal Enhancers Epigenetic Process Event Exposure to Future Gene Expression Gene Expression Profile Genes Genetic Genetic Transcription Genomics HIV HIV Infections HIV-associated neurocognitive disorder Hippocampus (Brain)Human In Situ Hybridization Individual Infection Insula of Reil Knowledge Link M cell Maps Mediation Molecular Mus National NeuroAids Tissue Consortium Neurobiology Neurocognitive Deficit Neuronal Injury Nucleic Acid Regulatory Sequences Nucleus Accumbens Opioid Pathway interactions Patients Pharmacology Phenotype Predisposition Prefrontal Cortex Process Property Proteins RNA Regulator Genes Resolution Resources Sampling Self Administration Specificity Substance Addiction Substance Use Disorder Untranslated RNA Validation Variant Ventral Tegmental Area Viral Load result Withdrawal Symptom addiction antiretroviral therapy base cell type chronic infection cocaine self-administration cocaine use cohort disorder control epigenomics experience genetic signature genome-wide human tissue immune function in vivo in vivo Model mortality mouse model nervous system disorder neuroinflammation new therapeutic target novel therapeutics opioid use response single-cell RNA sequencing substance use therapeutic target trait transcriptome transcriptomics

项目摘要

Abstract Substance use disorder (SUD) is a common and debilitating condition characterized by compulsive use of an addictive substance, inability to control the use of this substance, and the emergence of withdrawal symptoms in the absence of the substance. Despite great advances in our understanding of changes that occur in various brain regions in the context of addiction/SUD, there is a limited understanding of the diversity of cell types and gene expression profiles of cells within these human brain regions, and how exposures to addictive substances such as opioids and cocaine influence the molecular properties and functions of these cells. Over 50% of HIV- infected patients experience neurological disorders collectively termed HIV-Associated Neurocognitive Disorders (HAND), which ranges from the asymptomatic neurocognitive impairment to severely disabling dementia. The use of addictive substances by HIV-infected individuals has been linked to diminished immune function, increased neuroinflammation and neuronal injury, and exacerbation of HAND. Here, we seek to directly dissect the common and distinct molecular bases of SUD/HIV infection/HAND effects on distinct cell types by systematic profiling, dissection, computational integration, and experimental validation of their transcriptional, epigenomic, and genetic signatures across individuals, brain regions, and cell types. Aim 1: We use genetic, epigenomic, and transcriptional profiles, generating a total of ~28 million genome-wide maps at the single-cell (sc) level using 2,800 samples with 10,000 cells per sample; these span 7 brain regions (prefrontal cortex, nucleus accumbens, ventral tegmental area, dorsal striatum, insula, amygdala, hippocampus), two assays (scRNA, scATAC), four phenotypic groups (SUD+/HIV+, SUD+/HIV-, SUD-/HIV+, SUD-/HIV-), and a total of 200 subjects (50 in each phenotypic group). Aim 2: We integrate these datasets to predict driver genes, regulatory regions, variants, and pathways, and the cell types and brain regions where they act. Aim 3: We validate high-priority findings at the molecular level, and functionally validate the highest priority targets’ ability to modulate addictive behaviors in mouse models of in vivo cocaine self-administration. The resulting datasets will help guide the search for new therapeutics, by providing detailed therapeutic targets, and the specific conditions where they are predicted to act.

抽象的药物使用障碍（SUD）是一种常见且令人衰弱的疾病，其特征是强迫使用添加物质，无法控制这种物质的使用以及出现提款符号在没有物质的情况下。尽管我们理解了各种变化大脑区域在成瘾/SUD的背景下，对细胞类型的多样性和这些人脑区域内细胞的基因表达谱，以及如何暴露于其他物质例如阿片类药物和可卡因会影响这些细胞的分子特性和功能。超过50％的HIV- 感染的患者经历了神经疾病，共同称为HIV相关的神经认知疾病（手），范围从无症状的神经认知障碍到严重致残失智。艾滋病毒感染者使用添加剂的使用已与免疫力降低有关功能，神经炎症和神经元损伤增加以及手的加剧。在这里，我们试图直接剖析SUD/HIV感染/手部对不同细胞的常见和独特的分子碱基通过系统的分析，解剖，计算集成和实验验证的类型跨个体，大脑区域和细胞类型的转录，表观基因组和遗传特征。目标1：我们使用遗传，表观基因组和转录曲线，在总共约2800万个基因组地图上产生单细胞（SC）水平使用2,800个样品，每个样品有10,000个细胞；这些跨越了7个大脑区域（前额叶皮层，伏隔核，腹侧盖区域，背纹状体，岛岛，杏仁核，，杏仁核，海马），两个测定（SCRNA，SCATAC），四个表型组（SUD+/HIV+，SUD+/HIV-，SUD-/HIV+， SUD-/HIV-），共有200名受试者（每个表型组为50名）。目标2：我们将这些数据集集成到预测驱动基因，调节区域，变体和途径，以及细胞类型和大脑区域他们行动。 AIM 3：我们在分子水平上验证高优先级发现，并在功能上验证最高优先目标在体内可卡因自我管理的小鼠模型中调节其他行为的能力。由此产生的数据集将通过提供详细的治疗来帮助指导寻找新疗法目标，以及预测其行动的特定条件。